INGREZZA sales guidance for fiscal 2023 reflects expected sales of INGREZZA in tardive dyskinesia only. The guidance range is based upon recent trends and underlying business initiatives underway to help advance the development of the tardive dyskinesia market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
- Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley
- Xenon Pharmaceuticals outlines key milestone opportunities for 2023
- Voyager, Neurocrine enter collaboration to advance multiple gene therapies
- Neurocrine: FDA accepts sNDA for valbenazine